Acute leukemias (ALs) are relatively rare cancers in adults and require management that is increasingly complex and multidisciplinary. Relative to leukemias in children, where a vast majority of cases are treated in specialized cancer centers, adult ALs are currently managed across a variety of treatment settings and oncology practices. Emerging literature is demonstrating the utility of treating adult acute myeloid leukemia and adult acute lymphoblastic leukemia at specialized cancer centers, with initial studies showing that therapeutic approaches and AL outcomes may differ depending on treatment setting. In this Blood Advances Talk, we discuss the issue and review the available data linking access to specialized care with outcomes in adult ALs.

Correspondence: Lori Muffly, Stanford University, 300 Pasteur Dr, H0144, Stanford, CA 94304; e-mail: lmuffly@stanford.edu.

Author notes

Download or subscribe to the Blood Advances Talk podcast at https://soundcloud.com/blood-advances.

The complete text of this Blood Advances Talk is available as a data supplement.

Contribution: L.M. and V.R.B. wrote the manuscript.

Competing Interests

Conflict-of-interest disclosure: V.R.B. reports serving as a consultant for Pfizer, CSL Behring, Agios, Partner Therapeutics, AbbVie, and Incyte and has received research funding from Incyte, Tolero, and the National Marrow Donor Program. L.M. reports serving as a consultant for Pfizer, Amgen, Grail, and Kite and has received research funding from Adaptive and Shire.

Supplemental data